{"id":8875,"date":"2024-09-13T15:03:55","date_gmt":"2024-09-13T08:03:55","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=8875"},"modified":"2024-09-13T15:03:55","modified_gmt":"2024-09-13T08:03:55","slug":"aurora-biosynthetics-launches-to-revolutionize-rna-therapeutics-manufacturing","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=8875","title":{"rendered":"Aurora Biosynthetics Launches to Revolutionize RNA Therapeutics Manufacturing"},"content":{"rendered":"

SYDNEY<\/span>, Sept. 13, 2024<\/span> \/PRNewswire\/ —\u00a0Aurora Biosynthetics, a pioneering advanced RNA therapeutics manufacturing company, announced its official launch. This heralds a new era in RNA therapeutics manufacturing across the Asia-Pacific<\/span> region. Aurora Biosynthetics is poised to meet the surging demand for advanced RNA-based therapies by providing a complete end-to-end solution for Good Manufacturing Practice (GMP) production of plasmid DNA (pDNA), messenger RNA (mRNA), and lipid nanoparticles (LNP).<\/p>\n

Strategic Collaboration with the NSW Government, RNA Australia and Myeloid Therapeutics<\/p>\n

Aurora Biosynthetics reflects a strategically important, public-private partnership between the New South Wales<\/span> (NSW) Government, RNA Australia and Myeloid Therapeutics, a leader in RNA immunotherapies. This collaboration combines cutting-edge RNA manufacturing capabilities with strong support from the NSW Government, supporting Aurora’s rapid build, scale-up and robust entry into the global RNA manufacturing market.<\/p>\n

The NSW Government committed AU$200 million in support of the RNA ecosystem in Australia<\/span>, and it accepted the construction costs associated with building this state-of-the-art manufacturing facility. The facility is co-located on Macquarie University, in Sydney<\/span>, NSW, in a location that uniquely positions Australia<\/span> to make gains across the RNA field, including fostering collaboration with leading academic researchers and ensuring access to a highly skilled workforce.<\/p>\n

Comprehensive RNA Manufacturing Capabilities<\/p>\n

Aurora Biosynthetics is uniquely positioned to provide a fully-integrated RNA manufacturing solution that will enable product creation, development and commercialization, including:<\/p>\n

GMP Plasmid Production: Essential for supporting cell and gene therapies, as well as mRNA production GMP RNA Production: Specializing in the production of RNA GMP Lipid Nanoparticle Production: Offering LNP encapsulation for mRNA and other active pharmaceutical ingredients (APIs) using the latest technologies Fill-Finish Services: Providing final formulation and fill-finish capabilities for clinical trial and commercial use <\/p>\n

This comprehensive suite of services enables Aurora to offer a streamlined, one-stop solution that reduces complexity and accelerates time-to-market for its collaborators and clients.<\/p>\n

Vision for the Future<\/p>\n

Aurora will address the growing market need for high-quality RNA therapeutics manufacturing, within the rapidly expanding field of cell and gene therapies. With a projected compound annual growth rate (CAGR) of over 20% for cell and gene therapies, Aurora’s heritage keeps it well-positioned to become the GMP manufacturer of choice for the Asia-Pacific<\/span> region and beyond.<\/p>\n

Aurora’s leadership team combines deep expertise in RNA technology development and manufacturing.\u00a0 The team is focused on scaling the business to attain a compelling financial foundation.<\/p>\n

Economic Impact and Support for Innovation<\/p>\n

Clients utilizing Aurora Biosynthetics services are also set to benefit from Australia’s<\/span> R&D tax credit, which offers a 43% cash back on R&D spend, further incentivizing RNA client customers to bring their programs to Australia<\/span>. This, combined with the strong support from the NSW Government, positions Aurora as a critical player in the global RNA manufacturing landscape.<\/p>\n

About Aurora Biosynthetics<\/p>\n

Aurora Biosynthetics is a cutting-edge RNA manufacturing company dedicated to providing an end-to-end solution for the production of pDNA, mRNA, and LNPs. Based in Sydney, Australia<\/span>, Aurora leverages strategic partnerships and public-private collaboration to meet the growing global demand for RNA-based therapies. As a subsidiary of Myeloid Therapeutics, Aurora is committed to advancing the field of RNA therapeutics and delivering exceptional value to its customers.<\/p>\n

For more information, please visit www.aurorabiosynthetics.com<\/a> or contact us at info@aurorabiosynthetics.com<\/a>.\u00a0<\/p>\n

Logo – https:\/\/mma.prnasia.com\/media2\/2503707\/Aurora_Biosynthetics_Logo.jpg?p=medium600<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SYDNEY<\/span>, Sept. 13, 2024<\/span> \/PRNewswire\/ —\u00a0Aurora Biosynthetics, a pioneering advanced RNA therapeutics manufacturing company, announced its official launch. This heralds a new era in RNA therapeutics manufacturing across the Asia-Pacific<\/span> region. Aurora Biosynthetics is poised to meet the surging demand for advanced RNA-based therapies by providing a complete end-to-end solution for Good Manufacturing Practice (GMP) production of plasmid DNA (pDNA), messenger RNA (mRNA), and lipid nanoparticles (LNP).<\/p>\n

Strategic Collaboration with the NSW Government, RNA Australia and Myeloid Therapeutics<\/p>\n

Aurora Biosynthetics reflects a strategically important, public-private partnership between the New South Wales<\/span> (NSW) Government, RNA Australia and Myeloid Therapeutics, a leader in RNA immunotherapies. This collaboration combines cutting-edge RNA manufacturing capabilities with strong support from the NSW Government, supporting Aurora’s rapid build, scale-up and robust entry into the global RNA manufacturing market.<\/p>\n

The NSW Government committed AU$200 million in support of the RNA ecosystem in Australia<\/span>, and it accepted the construction costs associated with building this state-of-the-art manufacturing facility. The facility is co-located on Macquarie University, in Sydney<\/span>, NSW, in a location that uniquely positions Australia<\/span> to make gains across the RNA field, including fostering collaboration with leading academic researchers and ensuring access to a highly skilled workforce.<\/p>\n

Comprehensive RNA Manufacturing Capabilities<\/p>\n

Aurora Biosynthetics is uniquely positioned to provide a fully-integrated RNA manufacturing solution that will enable product creation, development and commercialization, including:<\/p>\n

GMP Plasmid Production: Essential for supporting cell and gene therapies, as well as mRNA production GMP RNA Production: Specializing in the production of RNA GMP Lipid Nanoparticle Production: Offering LNP encapsulation for mRNA and other active pharmaceutical ingredients (APIs) using the latest technologies Fill-Finish Services: Providing final formulation and fill-finish capabilities for clinical trial and commercial use <\/p>\n

This comprehensive suite of services enables Aurora to offer a streamlined, one-stop solution that reduces complexity and accelerates time-to-market for its collaborators and clients.<\/p>\n

Vision for the Future<\/p>\n

Aurora will address the growing market need for high-quality RNA therapeutics manufacturing, within the rapidly expanding field of cell and gene therapies. With a projected compound annual growth rate (CAGR) of over 20% for cell and gene therapies, Aurora’s heritage keeps it well-positioned to become the GMP manufacturer of choice for the Asia-Pacific<\/span> region and beyond.<\/p>\n

Aurora’s leadership team combines deep expertise in RNA technology development and manufacturing.\u00a0 The team is focused on scaling the business to attain a compelling financial foundation.<\/p>\n

Economic Impact and Support for Innovation<\/p>\n

Clients utilizing Aurora Biosynthetics services are also set to benefit from Australia’s<\/span> R&D tax credit, which offers a 43% cash back on R&D spend, further incentivizing RNA client customers to bring their programs to Australia<\/span>. This, combined with the strong support from the NSW Government, positions Aurora as a critical player in the global RNA manufacturing landscape.<\/p>\n

About Aurora Biosynthetics<\/p>\n

Aurora Biosynthetics is a cutting-edge RNA manufacturing company dedicated to providing an end-to-end solution for the production of pDNA, mRNA, and LNPs. Based in Sydney, Australia<\/span>, Aurora leverages strategic partnerships and public-private collaboration to meet the growing global demand for RNA-based therapies. As a subsidiary of Myeloid Therapeutics, Aurora is committed to advancing the field of RNA therapeutics and delivering exceptional value to its customers.<\/p>\n

For more information, please visit www.aurorabiosynthetics.com<\/a> or contact us at info@aurorabiosynthetics.com<\/a>.\u00a0<\/p>\n

Logo – https:\/\/mma.prnasia.com\/media2\/2503707\/Aurora_Biosynthetics_Logo.jpg?p=medium600<\/a>\u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-8875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8875"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8875\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}